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The Polycomb group and oncogene Bmi1 is required for the proliferation of various differentiated
cells and for the self-renewal of stem cells and leukemic cancer stem cells. Repression of the
Ink4a/Arf locus is a well described mechanism through which Bmi1 can exert its proliferative effects.
However, we now demonstrate in an orthotopic transplantation model for glioma, a type of cancer
harboring cancer stem cells, that Bmi1 is also required for tumor development in an Ink4a/Arf-
independent manner. Tumors derived from Bmi1;Ink4a/Arf doubly deficient astrocytes or neural
stem cells have a later time of onset and different histological grading. Moreover, in the absence
of Ink4a/Arf, Bmi1-deficient cells and tumors display changes in differentiation capacity.INTRODUCTION
The Polycomb group (PcG) gene and epigenetic silencer
Bmi1was originally identified as a collaborating oncogene
in the induction of lymphoma (Haupt et al., 1991; van
Lohuizen et al., 1991) and was subsequently reported
overexpressed in various human cancers (Valk-Lingbeek
et al., 2004). Its oncogenic function has mainly been
contributed to its repressive effect on the Ink4a/Arf tumor
suppressor locus (Jacobs et al., 1999). However, recent
studies have demonstrated that PcG proteins bind to mul-
tiple regions of the genome and therefore should have
several additional targets (Boyer et al., 2006; Bracken
et al., 2006; Lee et al., 2006; Negre et al., 2006; Tolhuis
et al., 2006). In line with this, we observed that while dele-
tion of the Ink4a/Arf locus can rescue a number of Bmi1
knockout phenotypes, other deficiencies in, for instance,
the brain remain (Bruggeman et al., 2005). Therefore, we328 Cancer Cell 12, 328–341, October 2007 ª2007 Elsevier Incdecided to test whether Bmi1 is required in an Ink4a/Arf-
independent manner for the formation of high-grade
glioma, an incurable cancer of the brain.
Gliomas can be divided into WHO grade II–IV tumors
(Kleihues et al., 2002). Grade II to III tumors consist of glial
cells only and are classified as either astro-, oligo-, or
mixed oligoastrocytomas. Grade IV tumors have a variable
appearance and are sometimes referred to as glioblas-
toma multiforme (GBM). They contain necrotic areas
surrounded by pseudopalisading tumor cells, regularly
display hyperproliferation of the endothelium, and some-
times exhibit neuronal differentiation. GBM can develop
de novo (primary GBM) or from a preexisting lower grade
glioma (secondary GBM). Interestingly, it has been dem-
onstrated that human GBM harbors ‘‘tumor-initiating
cells’’ or ‘‘cancer stem cells’’ (CSCs) (Galli et al., 2004;
Hemmati et al., 2003; Singh et al., 2004). CSCs represent
a rare subpopulation of cells within the tumor bulk thatSIGNIFICANCE
The Polycomb group and oncogene Bmi1 prevents premature growth arrest in most differentiated tissue cells and
is essential for the self-renewal of several types of adult stem cells. Previous studies documented the Ink4a/Arf
tumor suppressor locus as the main target mediating these activities. However, not all defects in the Bmi1 knock-
out mouse can be contributed to Ink4a/Arfmisregulation, suggesting additional factors to be involved. Our current
report that Bmi1 plays a role in pathways controlling proliferation, adhesion, and differentiation in mouse brain
cancer in an Ink4a/Arf-deficient background highlights that Bmi1 controls multiple processes in association
with genes other than Ink4a/Arf..
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transplantation. They have been identified in a number of
solid cancers as well as leukemia (Al Hajj et al., 2003; Bon-
net and Dick, 1997; Lapidot et al., 1994). CSCs share fea-
tures with normal adult stem cells like the expression of
primitive markers and capability to self-renew and differ-
entiate. Consequently, genes controlling normal stem
cells may also play a role in the cancer stem cell compart-
ment. From this respect, it is particularly interesting that,
in addition to a requirement for the proliferation of a variety
of differentiated cells, Bmi1 has been shown to be essen-
tial for the proliferation and self-renewal of several adult
stem cells, among which are the neural stem cells
(NSCs) of the subventricular zone (SVZ) (Bruggeman
et al., 2005; Leung et al., 2004; Molofsky et al., 2003;
Molofsky et al., 2005; Park et al., 2003; Zencak et al.,
2005). Moreover, Bmi1 is necessary for the propagation
of leukemic stem cells and is expressed in glioma stem
cells (Hemmati et al., 2003; Lessard and Sauvageau,
2003).
Recent advances in glioma modeling in the mouse
have made the disease amenable to in vivo functional
and molecular genetic studies (Fomchenko and Holland,
2006). Taking into account that the hypothesis that fully
differentiated astrocytes act as cell of origin for glioma
is currently challenged by studies demonstrating that
NSCs or progenitors serve as source (Sanai et al., 2005;
Zhu et al., 2005), we took advantage of an existing ortho-
topic transplantation model in which either primary NSCs
or astrocytes are used as cell of origin for the disease
(Bachoo et al., 2002). In this model, two mutations
frequently found in GBM are employed: deficiency for
Ink4a/Arf in combination with a constitutively active
mutant EGF receptor (*EGFR) (Ekstrand et al., 1992;
Nishikawa et al., 1994; Zhu and Parada, 2002). In tissue
culture experiments, we observed that Bmi1 absence in
an Ink4a/Arf-deficient background inhibits *EGFR induced
transformation and found this effect reflected in vivo.
Bmi1-deficient tumors form with a later onset, have differ-
ent histological grading, and exhibit reduced neuronal dif-
ferentiation, suggesting that Bmi1, independently from
repression of the Ink4a/Arf locus, regulates growth and
fate of glioma tumor cells.
RESULTS
Bmi1 Is Required for In Vitro Transformation
of Ink4a/Arf-Deficient Astrocytes
Before studying the role of Bmi1 in the development of
brain cancer from NSCs and astrocytes, we verified that
Bmi1 is expressed in these cells in vivo (Figure 1A; Figures
S1A and S1B in the Supplemental Data available with this
article online). We found that Bmi1 is present in most brain
cells and that expression is particularly high in the SVZ, the
major neurogenic region where the stem cells and progen-
itors reside. Identical results were obtained with Ink4a/
Arf/ mice (Figures S1C–S1E).
Next, we set out to assess whether absence of Bmi1
has an effect on the proliferative capacity of cortical astro-Cacytes. Hereto, we isolated primary cell cultures from cere-
bral cortices from 7-day-old mice according to estab-
lished methods, taking care to avoid the SVZ region.
These polyclonal cultures contained approximately 70%
GFAP+ (glial fibrillary acidic protein, an astroglial marker)
cells and were negative for Nestin or TuJ1 (progenitor
and neuronal markers, respectively) (Figures S2A, S2C,
and S2E). Since in vivo (though not in vitro) GFAP also
labels SVZ stem cells (Doetsch et al., 1999; Garcia et al.,
2004; Imura et al., 2003; Laywell et al., 2000; Figure
S10D), we investigated the expression of another progen-
itor marker, the carbohydrate LeX/SSEA-1/CD15 (Imura
et al., 2006). This marker is only rarely found on cells in
our cultures and its expression is not significantly different
between Ink4a/Arf/ and Bmi1/;Ink4a/Arf/ cultures
(Figures S2B and S2D). Hence, we will refer to these cul-
tures as astrocytes, even if formally a minor contamination
of more primitive cells cannot be ruled out.
In a 3T3proliferation assay,Bmi1/ astrocytes undergo
premature growth arrest (Figure 1B). Codeletion of the
Ink4a/Arf locus rescues this phenotype and immortalizes
Bmi1/ cells. However, derepression of the Ink4a/Arf
locus is not causing all Bmi1/ abnormalities (Figure S3)
(Bruggeman et al., 2005). Therefore, we set out to find
Ink4a/Arf-independent functions for Bmi1 in a model sys-
tem for in vitro transformation of Ink4a/Arf/ astrocytes
(Bachoo et al., 2002). In this model, primary Ink4a/Arf/
astrocytes deprived from serum but stimulated with the
growth factor EGF in defined NSC growth medium rap-
idly undergo morphological changes resembling loss-of-
contact inhibition and acquisition of anchorage-indepen-
dent growth, both hallmarks of transformation (Freedman
and Shin, 1974; Wang, 2004). For simplicity, we will refer
to this phenotype as EGF-induced transformation. First,
we verified that this feature was due to Ink4a/Arf absence
and not to contaminating progenitor cells. Hereto, we
isolated astrocytes engineered with LoxP sites flanking
the Ink4a/Arf locus. We only found clear morphological
changes upon EGF stimulation when they were trans-
duced with a Cre-recombinase, which causes the region
between the LoxP sites to be acutely excised from the ge-
nome (Figure 1C). Remarkably, Ink4a/Arf/ cells lacking
Bmi1 are completely incapable of adopting the trans-
formed morphology, which demonstrates that Bmi1 is
involved in transformation in an Ink4a/Arf-independent
manner (Figure 1D). Importantly,we couldmimic this by re-
moving Bmi1 from Ink4a/Arf/ cells using a short hairpin
vector against Bmi1 (shBmi1) (Figure 1E). This shRNA
had efficiently removed Bmi1 mRNA (Figure 1F) and pro-
tein (Figure 1G). Notably, we observed a minor induction
of both Bmi1mRNA (Figure 1H) and protein (Figure 1I) dur-
ing the process of transformation.
Immunophenotypical analysis revealed that both
control and Bmi1-deficient cells stimulated with EGF for 2
weekswere positive forGFAP, LeX, andNestin (Figure 2A).
If they were subsequently treated with 2% serum (FBS)
for 5 days, control cultures partially switched off the
stem/progenitor markers and started to generate TuJ1+
neurons (Figure 2B). However, the Bmi1/;Ink4a/Arf/ncer Cell 12, 328–341, October 2007 ª2007 Elsevier Inc. 329
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Bmi1 Controls Glioma Development and FateFigure 1. Bmi1 Is Required for Transformation of Ink4a/Arf/ Primary Astrocytes
(A) Immunohistochemical staining for Bmi1 protein in neurons of the cerebellum, cortex, and hippocampus (middle and right top panels, middle
bottom panel), and astrocytes of the corpus callosum (left panel). Particularly high Bmi1 expression in the SVZ (left panel). No Bmi1 was detected
in the Bmi1/ hippocampus (right bottom panel).
(B) 3T3 proliferation assay of primary astrocyte cultures. Cells were passaged every 3 days.
(C) Astrocytes engineered with LoxP sites flanking the Ink4a/Arf locus are transduced with Cre-recombinase or control retrovirus. They were
subjected to EGF stimulation and serum withdrawal for 14 days and scored for morphological changes.
(D) (Bmi1/;)Ink4a/Arf/ astrocyte cultures were stimulated with EGF for 2 days (left panels) or 15 days (right panels) in the absence of serum. Note
marked differences in transformed morphology.
(E) Ink4a/Arf/ astrocytes were transduced with retrovirus expressing an shRNA against Bmi1 (shBmi1) or a control shRNA against GFP (shGFP) and
subsequently stimulated with EGF for 14 days in the absence of serum.
(F and G) Reduced Bmi1 mRNA (F) and protein (G) levels in astrocytes transduced with shBmi1 as demonstrated by qRT-PCR and western blot
analysis, respectively.
(H) Induced Bmi1 mRNA and (I) protein levels upon stimulation of Ink4a/Arf/ astrocytes with EGF in the absence of serum in time.
Error bars represent the average of two independent experiments ± SD (B, F, and H)populations hardly ever contained neurons. To test if
rare LeX+ cells were responsible for these phenotypes,
we sorted both Ink4a/Arf/ and Bmi1/;Ink4a/Arf/ as-
trocyte cultures into LeX positive and negative fractions
(Figure S4A), stimulated these cells for 2 weeks with
EGF, and subsequently induced differentiation for 5 days330 Cancer Cell 12, 328–341, October 2007 ª2007 Elsevier Inc.with 2% FBS (Figure S4B). We found no differences be-
tween the positive and negative fractions, neither in trans-
forming capacity nor inmarker expression, suggesting that
LeX+ cells are not exclusively capable of undergoing
EGF-induced transformation or generating neurons. Im-
portantly, LeX+ Bmi1-deficient fractions were no more
Cancer Cell
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terization of EGF Stimulated Astrocytes
(A) (Bmi1/;)Ink4a/Arf/ astrocyte cultures
were stimulated with EGF for 14 days in the
absence of serum. They were stained for
LeX/SSEA-1/CD15 (green, left panels), Nestin
(green, middle panels) or TuJ1 (green, right
panels) and GFAP (red, right panels). Nuclei
were counterstained with DAPI (blue).
(B) Following 14 days of EGF stimulation,
(Bmi1/;)Ink4a/Arf/ astrocyte cultures
were treated with 2% serum (FBS) for 5 days.
They were stained for LeX/SSEA-1/CD15
(green, left panels), Nestin (green, middle
panels) or TuJ1 (green, right panels) and
GFAP (red, right panels). Note that fewer
Bmi1-deficient cells were TuJ1 positive. Nuclei
were counterstained with DAPI (blue).capable of transforming than LeX fractions. But we did
again observe a dramatic reduction in the number of
TuJ1+ cells generated, both from LeX+ and LeX Bmi1-
deficient cells.Of note, under serumconditions, LeX+ frac-
tions rapidly downregulated LeX expression (data not
shown).
Bmi1-Deficient Astrocytes Have an Impaired
Proliferative Response
For some experiments, instead of administering EGF,
we overexpressed a constitutively active EGF receptor
(EGFR) mutant. This EGFR (also EGFRvIII, DEGFR, or
*EGFR), derived from human glioma, confers growth
factor-independent growth on astrocytes (Bachoo et al.,
2002; Ekstrand et al., 1992; Holland et al., 1998; Nishikawa
et al., 1994). Under serum conditions, Bmi1/;Ink4a/
Arf/ astrocytes transduced with either empty vector or
*EGFR retrovirus proliferate at a significantly lower rate
(Figure S5A). Measuring BrdU uptake during *EGFR-
induced transformation in serum-free conditions also
revealed a delayed proliferative response in Bmi1/;
Ink4a/Arf/ cells (Figure S5B). Since Bmi1 represses
Ink4a/Arf, we tested whether Bmi1 absence induces other
cell cycle inhibitors. We could not find an increase in
p15Ink4a, p21cip1, p27kip1, or p53 proteins (Figure S5C),
nor could we detect any changes in mRNA levels for
p15Ink4b, p18Ink4c, or p19Ink4d (data not shown). We did
notice that in the absence of Bmi1, endogenous EGFR
levels were increased (Figure S5D).CaTo rule out the possibility of improper EGFR expression,
we overexpressed either wild-type (WT) or *EGFR in
Bmi1/;Ink4a/Arf/ astrocytes (Figure S5F), but trans-
formation was still impaired (Figure S5E). Next, we overex-
pressed different combinations of effector domain
mutants of oncogenic H-Ras in Ink4a/Arf/ control cells
(Figure S6B) (Rangarajan et al., 2004; Rodriguez-Viciana
et al., 1997) and observed that activation of at least two
known EGFR downstream pathways (Ral-GEF or PI3
kinase activation together with Raf pathway activation) is
sufficient to induce transformation (Figure S6A). But as
assessed by ERK, Akt, or FAK phosphorylation, down-
stream effectors were not differentially activated by EGF
in Bmi1 null cells, indicating that no common EGFR tar-
gets are mediating the phenotype (Figures S5G and
S6E). Lastly, we established that inhibition of transfor-
mation of Bmi1/;Ink4a/Arf/ astrocytes is not EGFR
specific since these cells are also resistant against
H-RasV12 or TrkB/BDNF induced transformation (Figures
S6C and S6D). However, these transformation defects are
cell type specific as we also performed a number of trans-
formation assays on embryonic mouse fibroblasts, but
here, we did not find any differences (Figure S7).
BMI1 Is Expressed in Human Glioma and Required
for In Vivo Transformation and Differentiation
of Ink4a/Arf-Deficient Astrocytes
In normal human brain, we find nuclear BMI1 expression
in the vast majority of cells (Figure 3A) similar to mice.ncer Cell 12, 328–341, October 2007 ª2007 Elsevier Inc. 331
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Normal Human Brain Tissue and Brain
Tumors
(A) Immunohistochemical staining for BMI1 in
different areas of the human brain.
(B and C) Immunohistochemical staining for
BMI1 in human neurocytoma and low-grade
glioma (B) and in high-grade glioma (C).Substantiating the idea that BMI1 has a function in human
glioma is the finding that the protein is expressed in almost
all human brain tumors analyzed, such as lower grade
astro-, oligo-, or oligoastrocytomas and neurocytomas
(Figure 3B) and in high-grade gliomas and GBM
(Figure 3C).
To demonstrate thatBmi1modulates in vivo gliomagen-
esis, we made use of an orthotopic transplantation model
in which *EGFR drives tumor growth of primary astrocytes
(Bachoo et al., 2002). (Bmi1/;)Ink4a/Arf/ *EGFR (or
empty vector as control) astrocytes (Figure 4C) were
stereotactically intracranially injected and allowed up to
4 months to form tumors (Figure 4A). In addition, these
cells were labeled with an EGFP-IRES-Luciferase con-
struct that allowed us to follow tumor growth noninva-
sively in vivo. We measured the time between tumor cell
injection and lethal tumor development and noticed a
dramatic prolongation of the survival of mice injected
with Bmi1/;Ink4a/Arf/ cells (Figure 4B), indicating
that Bmi1 facilitates tumor formation. Notably, empty
vector-transduced astrocytes do not form tumors,
demonstrating they are not tumorigenic. Using in vivo
bioluminescence, we observed a trend in which Ink4a/332 Cancer Cell 12, 328–341, October 2007 ª2007 Elsevier Inc.Arf/ *EGFR cells immediately formed tumors, while
Bmi1/;Ink4a/Arf/ *EGFR cells first went through
a lag phase (Figure 4D). Finally, tumor samples were
stained for a number of molecular markers and histologi-
cally analyzed by pathologists (Figure 4E). They resem-
bled human glioma, with the exception that hyperprolifer-
ation of the endothelium was only rarely present. Both
Ink4a/Arf/ and Bmi1/;Ink4a/Arf/ tumors developed
into grade III–IV (oligo)astrocytomas or GBM, whereby
Bmi1/;Ink4a/Arf/ tumors exhibited more pronounced
pseudopalisading aroundmicronecrotic areas.We did not
find any differences in proliferation in the tumors as deter-
mined by PCNA positivity (Figures S8A and S8B). In line
with the presence of stem cell-like cells, human GBM
regularly exhibit glial and neuronal differentiation in combi-
nation with expression of primitivemarkers. Corroborating
this, we found that the majority Ink4a/Arf/ tumors
exhibited immunopositive areas for the progenitor marker
Nestin (8/8), neuronal marker TuJ1 (5/8), and patchy
staining for astrocytic marker GFAP (8/8) (Figure 4E). In
contrast, only 3 out of 6 Bmi1/;Ink4a/Arf/ tumors
were positive for Nestin, and only 1 tumor expressed
TuJ1.
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ment could be that the number of cells capable of growing
out into a tumor (i.e., the number of tumor-forming cells)
differs between Ink4a/Arf/ and Bmi1/;Ink4a/Arf/
cultures. To address this, we isolated genomic DNA
from the preinjected cells and from tumor-derived cells
and performed Southern blot analysis (Figure S9). We
made use of the fact that the cultures originally had
been transduced with *EGFR-Blasticidin containing retro-
viruses at an MOI of 1. Hence, we reasoned that each cell
must have one unique integration, with the result that the
polyclonal preinjected populations should appear as
a smear on the blot when visualized with a probe against
the Blasticidin resistance gene. Consequently, if any
selection had occurred during the process of tumor
formation, the tumor-derived cell populations would give
a banded pattern. This is exactly what we observed, and
importantly, there are no differences between the number
of bands of Ink4a/Arf/ versus Bmi1/;Ink4a/Arf/
cultures, indicating that approximately equal numbers of
tumor-forming cells were present.
Glial Cells Deficient for Bmi1 Undergo Significant
Changes in Gene Expression during
Tumorigenesis
The increased survival of mice receiving Bmi1/;Ink4a/
Arf/ cells together with the bioluminescence data sug-
gesting a lag phase before tumor formation led us to spec-
ulate that Bmi1-deficient cells undergo substantial
changes in gene expression before emerging into tumors.
To investigate this, we isolated cells from tumors and
compared their gene expression profile to the original
preinjected tumor-inducing cells using oligo-microarrays.
The control hybridizations (Ink4a/Arf/ *EGFR, n = 3 in-
dependent tumors) yielded an average of 601 outliers
(Figure 5A). In contrast, when hybridizing Bmi1/;Ink4a/
Arf/ cells (n = 6 independent tumors), we obtained an
average of 2950 outliers per experiment substantiating
our presumption. Next, we did clustering analysis on the
common outliers of the control and Bmi1/;Ink4a/Arf/
array experiments using Genesis software (Figures 5B
and 5D) (Sturn et al., 2002). The Ink4a/Arf/ control arrays
only had 54 outliers in common clustering into no obvious
patterns, whereas the common outliers from the Bmi1/;
Ink4a/Arf/ arrays (551 in total) strongly clustered and
were consistently up- or downregulated. These data
suggest that Bmi1-deficient cells not only undergo signif-
icantly more changes in gene expression during tumor
growth, but that they need to change expression of a spe-
cific group of genes to compensate for Bmi1 absence. To
obtain insight into the affected pathways, we analyzed the
data from three control versus three experimental arrays
using Ingenuity Pathway Analysis software (Ingenuity Sys-
tems, Redwood City, CA). This program translates ar-
ray data into ontological (functionally related) groups. In
Figure 5C, we show the eight most and two least signifi-
cantly affected groups in the Bmi1/;Ink4a/Arf/ arrays.
Most striking were ‘‘Cellular Movement,’’ ‘‘Growth and
Proliferation,’’ and ‘‘Tissue Development.’’CaBmi1-Deficient Neural Stem Cells Give Rise
to Lower Grade Glioma and Have Reduced
Differentiation Capacity
Next, we set out to demonstrate that NSCs, another can-
didate ‘‘cell type of origin’’ for GBM, require Bmi1 for
tumor development. For this purpose, we isolated primary
NSCs from Ink4a/Arf/ or Bmi1/;Ink4a/Arf/ adult
mouse SVZ. Importantly, we maintained these cells as
monolayers on poly-L-Ornithine and Laminin coated
dishes (Conti et al., 2005). Under serum-free stem cell
conditions, these cultures were 100% Nestin and LeX
positive and completely negative for GFAP and TuJ1,
implying a high degree of homogeneity (Figures S10A–
S10D). When induced to differentiate with 2% FBS for
7 days, both Ink4a/Arf/ and Bmi1/;Ink4a/Arf/ NSCs
efficiently generated GFAP- and TuJ1-positive cells
while completely switching off Nestin (Figure 6D, Figures
S10E and S10F). They were transduced with empty vector
or *EGFR (Figure 6B) and subsequently stereotactically
injected into the brain. Similar to the astrocyte experi-
ments, we observed a significant increase in survival of
mice receiving Bmi1/;Ink4a/Arf/ cells (Figure 6A),
confirming that Bmi1 facilitates a rapid onset of tumor
growth. Also, there was no difference in proliferation rate
between the tumors at the time of death (Figures S8C
and S8D). But unlike the astrocyte-derived tumors, we
did not find any GBM among the Bmi1/;Ink4a/Arf/
panel when we analyzed the tumors histologically,
whereas a number of control tumors was diagnosed as
such (Figure 6C). Also, none of the Bmi1-deficient tumors
exhibited pseudopalisading. This suggests that in the
absence of Bmi1, NSCs may not become fully malignant.
Immunostainings for Nestin, GFAP, and TuJ1 revealed
more differences (Figure 6C). Both types of tumors were
consistently positive for GFAP, but while all Ink4a/Arf/
tumors (7/7) were positive for Nestin, only half of the
Bmi1/;Ink4a/Arf/ tumors (4/7) showed Nestin stain-
ing. Even more striking, the majority of Ink4a/Arf/ (5/7)
tumors strongly expressed neuronal marker TuJ1 versus
1/7 Bmi1/;Ink4a/Arf/ tumors. All tumors were nega-
tive for Neurofilament and Synaptophysin, while some
but not all TuJ1+ tumors stained positive for MAP2 (data
not shown).
We next asked the question whether Bmi1/;Ink4a/
Arf/ NSCs also would have impaired neurogenic capac-
ity. Up to 10 passages (approximately 3 weeks) following
isolation,wecouldnotdetect anydifferences inneurogenic
capacity between Ink4a/Arf/ and Bmi1/;Ink4a/Arf/
NSCs (Figure 6D). However, at later time points,
Bmi1/;Ink4a/Arf/ NSCs lost their ability to efficiently
generate TuJ1+ neurons and GFAP+ astrocytes, whereas
control NSCscontinued to do so up to at least 30 passages
(Figures6Eand6F;FigureS10G).Notably,bothcontrol and
Bmi1-deficient NSCcultures remained completely positive
for Nestin under stem cell conditions (Figure 6E).
Altogether, these data demonstrate that Bmi1 is essen-
tial for the development of high-grade glioma from NSCs
and that multipotency becomes lost in the absence of
Bmi1, both in vitro and in vivo.ncer Cell 12, 328–341, October 2007 ª2007 Elsevier Inc. 333
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(A) Experimental set up: Ink4a/Arf/ orBmi1/;Ink4a/Arf/ primary astrocytes were transducedwith retroviruses containing no insert (empty vector
control, EV) or mutant EGFR (*EGFR) and cotransduced with an EGFP-IRES-Luciferase construct. Cells were stereotactically injected into the right
hemisphere of nude mice. At specific time points, tumor mass was determined by intraperitoneal injection of luciferine followed by quantification of
the amount of light emitted.Whenmice showed signsof tumor development, tumorswere isolated for histological analysis or derivation of cell cultures.
(B) Mice injected with Ink4a/Arf/ *EGFR astrocytes (n = 13) developed brain tumors between 26 and 43 days following injection, and mice injected
withBmi1/;Ink4a/Arf/ *EGFRastrocytes (n=12) developedbrain tumors significantly later, between42and91days (log-rank test, p=2.563107).
Mice injected with either Ink4a/Arf/ EV (n = 5) or Bmi1/;Ink4a/Arf/ EV astrocytes (n = 5) did not develop tumors.
(C) Western blot demonstrating equal *EGFR and EGFP expression levels in Ink4a/Arf/ (IA) or Bmi1/;Ink4a/Arf/ (BIA) astrocytes used for
stereotactic injections (shown are representative examples of different injected cell lines). Tub, alpha tubulin.
(D) Live imaging of tumor development by measuring bioluminescence of Ink4a/Arf/ *EGFR versus Bmi1/;Ink4a/Arf/ *EGFR tumors in time. A
trendwasobserved inwhichBmi1/;Ink4a/Arf/ tumorsdevelopedwith a later onset thancontrol tumors. Each line represents tumor growth kinetics
for one mouse, depicted are three representative examples for each experimental group.334 Cancer Cell 12, 328–341, October 2007 ª2007 Elsevier Inc.
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Bmi1 Controls Glioma Development and Fate(E) Histological analysis of astrocyte-derived brain tumors. Depicted are two representative examples from each experimental group. Both Ink4a/
Arf/ *EGFRandBmi1/;Ink4a/Arf/ *EGFR tumorswere classified asgrade III anaplastic (oligo)astrocytomas or grade IVglioblastomasmultiforme
(HE panels). Pseudopalisading (indicated by arrowheads) was more pronounced in Bmi1/;Ink4a/Arf/ tumors. 8/8 Ink4a/Arf/ tumors showed
strong Nestin positivity compared to 3/6 Bmi1/;Ink4a/Arf/ tumors (Nestin panels). 5/8 Ink4a/Arf/ tumors were positive for the neuronal marker
TuJ1 versus 1/6 Bmi1/;Ink4a/Arf/ tumors (TuJ1 panels). GFAP staining was patchy and similar between the two experimental groups (GFAP
panels). HE, hematoxylin & eosin; TuJ1, b-tubulin III.
Figure 5. Bmi1/;Ink4a/Arf/ *EGFR Astrocyte-Derived Tumor Cell Lines Have Undergone Substantial Changes in Gene
Expression
(A) Comparison of total outlier number between (Bmi1/;)Ink4a/Arf/ *EGFR preinjected and tumor-derived cell lines (n = 3 and 6 experiments,
respectively). Shown are the average numbers of outliers (range). Up indicates upregulated in the tumor cells.
(B) Clustering analysis of common outliers (n = 54 for the Ink4a/Arf/ *EGFR arrays versus n = 551 for Bmi1/;Ink4a/Arf/ *EGFR arrays) demon-
strates that Bmi1/;Ink4a/Arf/ *EGFR tumor cells consistently change their gene expression profile upon injection and tumor growth. A red signal
indicates higher gene expression in the tumor cells compared to the preinjected astrocytes, and green indicates lower gene expression. Note that we
applied less stringent criteria when combining all nine arrays (p > 0.01 allowed for 1 data point).
(C) Ontological pathway analysis reveals the 8 most (black text) and 2 least (blue text) significantly altered ontological gene groups upon tumor
development from Bmi1/;Ink4a/Arf/ cells. n = 3 Ink4a/Arf/ (IA) versus n = 3 Bmi1/;Ink4a/Arf/ (BIA) arrays.
(D) List of the most significantly up- and downregulated genes in the Ink4a/Arf/ *EGFR and Bmi1/;Ink4a/Arf/ *EGFR arrays.Cancer Cell 12, 328–341, October 2007 ª2007 Elsevier Inc. 335
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(A) Mice stereotactically injected with Ink4a/Arf/ *EGFR primary neural stem cells (n = 7) develop brain tumors between 32 and 50 days following
injection, mice injected with Bmi1/;Ink4a/Arf/ *EGFR cells (n = 7) develop brain tumors significantly later between 28 and 80 days (log-rank test,
p = 0.011). Mice receiving either Ink4a/Arf/ EV (n = 5) or Bmi1/;Ink4a/Arf/ EV (n = 8) cells developed no tumors.
(B) Western blot analysis demonstrates equal *EGFR expression levels in Ink4a/Arf/ (IA) or Bmi1/;Ink4a/Arf/ (BIA) stem cells (shown are
representative examples of different injected cell lines). CDK4, loading control.
(C) Histological analysis of NSC-derived brain tumors. Depicted are two representative examples from each experimental group. Both Ink4a/Arf/
*EGFR and Bmi1/;Ink4a/Arf/ *EGFR tumors contained grade III anaplastic (oligo)astrocytomas. However, in contrast to the Bmi1/;Ink4a/Arf/
*EGFR tumors, themajority of Ink4a/Arf/ *EGFR tumors showed clear pseudopalisading (arrowheads) and appearedmore aggressive. Some Ink4a/
Arf/ tumors were classified as grade IV glioblastoma multiforme (HE panels). 7/7 Ink4a/Arf/ tumors showed strong Nestin positivity compared to
4/7Bmi1/;Ink4a/Arf/ tumors (Nestin panels). 5/7 Ink4a/Arf/ tumors were positive for the neuronal marker TuJ1 versus 1/7Bmi1/;Ink4a/Arf/
tumors (TuJ1 panels). GFAP staining was similar between the two experimental groups (GFAP panels).
(D) Primary NSCs (up to 3 weeks following isolation) were induced to differentiate with 2% FBS for 7 days and stained for TuJ1 (green) or GFAP (red).
Nuclei were counterstained with DAPI (blue).336 Cancer Cell 12, 328–341, October 2007 ª2007 Elsevier Inc.
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Because of the many similarities between cancer and
normal stem cells, one can assume that processes regu-
lating stem cell proliferation and maintenance are also
fundamental to cancer stem cells. We attempted to elu-
cidate the role of PcG gene Bmi1 in the formation of
glioblastoma multiforme, one of the cancers driven by
a cancer stem cell subpopulation (Galli et al., 2004; Hem-
mati et al., 2003; Singh et al., 2004). Bmi1 has been
demonstrated to be essential for the proliferation and
self-renewal of leukemic stem cells (Lessard and Sauva-
geau, 2003), as well as normal neural stem cells by repres-
sing the Ink4a/Arf locus (Bruggeman et al., 2005; Molofsky
et al., 2005). In this study, we extended our scope and
specifically searched for Ink4a/Arf-independent functions
of Bmi1 in brain cancer.
Bmi1 Is Required for Proliferation
and Transformation of Primary Glial Cells
We used an established orthotopic transplantation model
to study transformation of brain cells in vitro and in vivo.
Taking into account that the cell-of-origin for glioma
(stem) cells is not necessarily a differentiated glial cell
and that Bmi1 is expressed in the vast majority of brain
cells, we aimed at analyzing the capacity of both primary
astrocytes and NSCs deficient for Ink4a/Arf to transform
upon EGF overstimulation in the absence of Bmi1. We
would like to note that, while we have attempted to estab-
lish pure astrocyte and neural stem cell cultures in compli-
ance with published methods, the current lack of markers
definitively distinguishing between terminally differenti-
ated astrocytes and more primitive ancestors urges for
some reticence when using these terms.
The induction of Bmi1 protein during in vitro transforma-
tion already hinted at a role for Bmi1 in this process.
Indeed, whereas control Ink4a/Arf/ astrocytes rapidly
undergo morphological changes typical of transformation
such as loss of contact inhibition and acquisition of
anchorage independent growth, in the absence of Bmi1,
these cells virtually lose this capacity. This is cell type
specific as there was no such difference in transforming
capacity of mouse fibroblasts. A number of alterations in
cell physiology have been proposed to be essential for
malignant growth (Hanahan and Weinberg, 2000). Among
these are self-sufficiency in growth signals, limitless repli-
cative potential, insensitivity to growth-inhibitory signals,
and tissue invasion and metastasis. The first two require-
ments are met by presence of *EGFR and deletion of
Ink4a/Arf. The reduced proliferative activity of Bmi1/;
Ink4a/Arf/ astrocytes may compromise the third hall-
mark and thus underlie the transformation defect. How-
ever, negation to change growth mode from adherentCatoward anchorage-independent suggests that pathways
implicated in cell-cell and cell-matrix interactions are
impaired as well, and this could impair the fourth trait.
Curiously, Bmi1/;Ink4a/Arf/ astrocytes can survive
and grow in suspension when plated onto ultra low-bind-
ing plates (S.B. and M.v.L., unpublished data), indicating
a preference to grow adherent rather than a complete
incapability to do so. Altering adhesive properties can be
beneficial to tumor cells in different ways. First, loss of
anchorage dependence protects cells from anoikis and
facilitates survival during metastasis. Second, invasion
and migration through the stroma entails both adhesion
and remodeling of the extracellular matrix (Gupta and
Massague, 2006). Notably, extensive migration through-
out the brain is a principal feature of malignant glioma
(Giese et al., 2003). In concert with our gene expression
studies revealing specific changes in adhesion-related
pathways in Bmi1/;Ink4a/Arf/ tumor cells, we pro-
pose that Bmi1-deficient cells are less tumorigenic due
to a combination of altered proliferative and adhesive
properties.
Bmi1-Deficiency Impedes Tumor Growth
and Biases toward a Less Malignant Phenotype
By intracranial injection of astrocytes and NSCs, we were
able to disclose a number of differences between tumors
derived from Ink4a/Arf/ and Bmi1/;Ink4a/Arf/ cells
in vivo. Both when using astrocytes and NSCs, we
observed a dramatic increase in survival of mice receiving
Bmi1-deficient cells. This can be explained by a general
reduction in tumor cell proliferation; however, no such
differences were evident at the time of death. An alter-
native explanation could be a difference in the number
of ‘‘tumor-initiating’’ cells present in Ink4a/Arf/ and
Bmi1/;Ink4a/Arf/ cell cultures, but Southern blot anal-
ysis demonstrating equal amounts of cells contributing to
tumorigenesis argues against this. Another possibility is
that Bmi1 knockout cells require a substantial amount of
time to adapt their gene expression such that a tumor
can form. This hypothesis is supported by the in vivo bio-
luminescence data portraying the Bmi1/;Ink4a/Arf/
tumors as residing in an initial phase of slow growth before
emerging into a tumor. Corroborating this, comparison of
gene expression profiles between preinjected and tumor
cells clearly showed that Bmi1/;Ink4a/Arf/ cells have
undergone significantly larger alterations in transcription
than control cells, and a core group of perfectly clustering
genes can easily be distilled. This ‘‘Bmi1 null profile’’ can
be dissected into a number of interesting gene networks.
Most outstanding is the ‘‘Cellular Movement’’ cluster
comprising cell movement, migration, chemotaxis, and
homing. This is well in accordance with our finding that
Bmi1-deficient astrocytes in culture exhibit impaired(E) NSCs between 3 and 10 weeks following isolation under stem cell conditions were stained for Nestin (green, right panels). They were differentiated
with 2% FBS for 7 days and stained for TuJ1 (green, left panels) or GFAP (red, left panels). Note the reduced generation of TuJ1+ cells in the absence
of Bmi1. Nuclei were counterstained with DAPI (blue).
(F) Phase contrast photographs of differentiated NSCs between 3–10 weeks following isolation showing fewer cells with neuronal morphology in the
absence of Bmi1.ncer Cell 12, 328–341, October 2007 ª2007 Elsevier Inc. 337
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lar Growth and Proliferation,’’ encompassing networks
involved in proliferation and colony formation. Again,
this is in agreement with our in vitro observation that
EGF-stimulated Bmi1/;Ink4a/Arf/ cells initially have
a reduced proliferative response. A role for a PcG gene
in adhesion is not without precedent. A recent study
demonstrated the involvement of Ezh2 in the dynamics
of the cytoskeleton (Su et al., 2005). As Ezh2 also stimu-
lates proliferation, regulating proliferation and adhesion
could be a universal PcG feature.
Because the Bmi1-deficient tumors arose at a later time
point, we anticipated they would differ histologically and
possibly also in terms of malignancy. Here, a difference
between the astrocyte- and NSC-derived tumors became
apparent. Both Bmi1-deficient and -proficient astrocytes
gave at approximately equal ratios rise to gliomas, which
according to pathologists, could be classified as grade
III anaplastic (oligo)astrocytomas or grade IV GBM. Pseu-
dopalisades, a typical feature of high-grade glioma, were
detected in all GBM-classified tumors. In contrast,
Bmi1-deficient NSCs never developed into tumors higher
graded than III and on no account showed pseudopali-
sading, whereas control cells readily did. Additionally,
Bmi1/;Ink4a/Arf/NSC tumors appeared histologically
distinct as they never exhibited extracranial growth but
instead spread widely through the hemispheres. This
discrepancy could relate to the cell-of-origin issue as,
apparently, astrocytes respond differently to Bmi1 ab-
sence than NSCs. Previous studies have ascribed more
importance to Bmi1 function in (cancer) stem cells than
differentiated cells (Hosen et al., 2007; Liu et al., 2006;
Molofsky et al., 2003; Prince et al., 2007). However, in ad-
dition to our observations that Bmi1 is abundantly
expressed in most brain (cancer) cells, we find that Bmi1
is essential for astrocyte proliferation, which strongly
argues that Bmi1 controls both stem cells and their
progeny. Therefore, we would rather propose that either
Bmi1 has additional functions in stem cells or, alterna-
tively, that stem cells are more reliant on common Bmi1
functions.
Bmi1-Deficient Glial Cells and Tumors Exhibit
Reduced Differentiation Capacity
Another altered ontological cluster in the Bmi1 null
common profile was related to development (‘‘Tissue De-
velopment’’). Knowing that PcG actively represses genes
involved in fate choice during embryogenesis (Boyer et al.,
2006; Bracken et al., 2006; Lee et al., 2006; Negre et al.,
2006; Tolhuis et al., 2006), we questioned whether Bmi1
deficiency would lead to alterations in differentiation
status of the tumors. In accordance with a stem cell com-
ponent, GBM cells sometimes differentiate toward the
neuronal in addition to the glial lineage (Katsetos et al.,
2001; Martinez-Diaz et al., 2003). Both our astrocyte-
and NSC-derived control tumors were positive for Nestin,
GFAP, and TuJ1, indicating that these tumors indeed
differentiate into all lineages. But, GBMs can be infiltrated
with reactive cells and are sometimes promiscuous in338 Cancer Cell 12, 328–341, October 2007 ª2007 Elsevier Inc.marker expression (Katsetos et al., 2001; Katsetos et al.,
2004). Therefore, we interpret TuJ1 positivity as an at-
tempt of the glioma cell to differentiate into the neuronal
lineage but do not conclude presence of mature neurons
from this. Nonetheless, it was striking that Bmi1/;
Ink4a/Arf/ tumors stained less frequently positive for
TuJ1, suggestive of impaired neuronal commitment. In
addition, they less prominently expressed stem cell
marker Nestin. One explanation for these observations is
that in absence of Bmi1, the total number of primitive cells
capable of differentiating is reduced due to impaired self-
renewal. Alternatively, Bmi1 is involved in the fate choice
of the progenitor cell. It was already shown that Bmi1/;
Ink4a/Arf+/+ neurospheres fail to efficiently produce neu-
rons upon differentiation (Zencak et al., 2005). Also, neu-
roblastoma cells differentiating in culture and in tumors
into Schwann-like cells (glial cell of the peripheral nervous
system) show reduced Bmi1 protein expression, whereas
cells differentiating into neuroblasts have higher levels of
Bmi1 (Cui et al., 2006, 2007). Moreover, acute removal
or overexpression of Bmi1 in these cells instructed them
to differentiate into the glial or neuronal lineage, respec-
tively. Our in vitro experiments corroborate an Ink4a/Arf-
independent role for Bmi1 in differentiation, since both
our Bmi1-deficient astrocytes and NSCs lost the capacity
to generate neurons. It is conceivable that Bmi1 has sim-
ilar effects on GBM cells in vivo.
Altogether, the Bmi1 characteristics described in this
study have considerable implications for understanding
PcG function in (stem) cells and cancer. Whereas previous
attention was focused on repression of the Ink4a/Arf
locus, we now clearly demonstrate that Bmi1 also regu-
lates alternative pathways involved in proliferation, adhe-
sion, and differentiation. It is likely that these pathways
are important both in the stem cell niche and in the
process of tumor development, in particular in cancers
associated with extensive migration and differentiation
of tumor (stem) cells such as glioblastoma.
EXPERIMENTAL PROCEDURES
Mice Breeding, Tissue Isolation, and Preparation
of Cell Cultures
Bmi1/ (Van der Lugt et al., 1994) and Ink4a/Arf/ mice (Serrano
et al., 1996) were in an FVB background. For orthotopic transplantation
studies, athymic (nude) FVB or Balb/c mice were used. Mice were
killed by an overdose of CO2 instantly followed by tissue isolation.
NSCs and MEFs were isolated as described before (Bruggeman
et al., 2005). NSCs were maintained in defined serum-free NSC
medium containing 20 ng/ml EGF and 10 ng/ml bFGF (R&D systems)
as adherent cultures on poly-L-Ornithine (15 mg/ml) and Laminin
(5 mg/ml, both Sigma) coated plates (Conti et al., 2005). Primary astro-
cyte cultures were derived from 7-day-old mice using established
methods (McCarthy and de Vellis, 1980). Briefly, neocortices were
isolated and washed. Tissue was triturated, digested for 20 min at
37C with Trypsin EDTA (Invitrogen)/DnaseI (Boehringer Mannheim)
solution, and quenched with astrocyte culture medium (DMEM/F12,
10% FBS, Invitrogen). Cell suspensions were passed through cell
strainers and plated in astrocyte culture medium.
All animal experiments were done conform national regulatory stan-
dards approved by the DEC (Animal Experiments Committee).
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and Transductions
Human WT EGFR and *EGFR derived from pLWERNL and pLERNL,
respectively (gift from Dr. W. Cavenee), were subcloned into retroviral
expression vector pMSCV blasticidin. An MSCV puromycin (Clon-
tech) construct containing Luciferase-IRES-GFP was provided by
Dr. A. Berns. pBABEpuro TrkB and pBABEhygro BDNF were gifts
from Dr. D. Peeper. H-RasV12 mutants (Rodriguez-Viciana et al.,
1997) were subcloned into MSCVpuro. For knockdown experiments, a
pRETRO-SUPER construct containing a sequence targeting Bmi1
(GTATTGTCCTATTTGTGAT) was used.
For retroviral transductions, see the Supplemental Data.
Cell Culture Experiments
For 3T3 proliferation assays, cells were passaged every 3 days and
counted. BrdU incorporation assays (1 hr pulse of 10 mM BrdU) were
done as described before (Bruggeman et al., 2005).
In vitro astrocyte transformation was studied by plating 30,000
primary cells in 6-well plates. They were incubated in NSC medium
containing 20 ng/ml EGF and scored for morphological changes after
14–15 days. For some experiments, EGF-induced cultures were
switched to NSC medium containing 2% FBS for 7 days. For soft
agar assays, 50,000 cells were seeded in 6-well plates in DMEM
containing FBS and 0.35% agar. Colony formation was scored after
3 weeks.
In vitro NSC differentiation was studied by plating 150,000 (adher-
ent) NSCs onto poly-L-Ornithine and Laminin coated coverslips in
6-well plates. They were incubated in NSC medium containing 2%
FBS for 7 days.
To study phosphorylation, astrocytes were serum starved overnight
and pulsed for 15 or 45min with 20 ng/ml EGF or 10% FBS followed by
immediate cell lysis in the presence of protease and phosphatase
inhibitors.
Western Blot Analysis, Immunofluorescence,
and Immunohistochemistry
Western blot analysis and immunofluorescence were done as
described previously (Bruggeman et al., 2005). For LeX/SSEA-1/
CD15 immunofluorescence, live cells were incubated with anti-LeX an-
tibody for 30min prior to fixation. For IHC stainings and antibodies, see
the Supplemental Data. Anonymous human brain (tumor) samples
were obtained from the Free University Medical Centre and the Sloter-
vaart Hospital (Amsterdam, the Netherlands) in agreement with the
national ‘‘code of adequate use of tissue,’’ approved by the METC
(medical-ethical review committee).
Stereotactic Brain Injections, Bioluminescence Imaging,
and Tumor Collection
A detailed description of the stereotactic brain injection and biolumi-
nescence procedures is given elsewhere (Kemper et al., 2006). In
short, anaesthetized mice were placed in a stereotact and 100,000
cells were injected 2 mm lateral and 1 mm anterior to the bregma,
3 mm below the skull. For some experiments, tumor-bearing mice
were injected intraperitoneally with 150 mg/kg luciferin (Xenogen),
anaesthetized, and recorded within 10–20 min using a cooled IVIS
camera (Xenogen Corp) twice a week. All mice were monitored for
tumor development for a period of 4 months and sacrificed when
they started to exhibit visible tumors or signs of sickness and weight
loss. All organs were routinely analyzed to confirm the brain tumor to
be the cause of death. Tumors were classified blindly by pathologists.
RNA Isolation, Quantitative Real-Time PCR,
and Oligoarray Analysis
qRT-PCR was performed as before (Bruggeman et al., 2005). Proto-
cols for oligoarray analysis can be downloaded from microarray.nki.nl.
Expression data is available from the EBI ArrayExpress database
(www.ebi.ac.uk/arrayexpress). EBI-ID: E-NCMF-4. See the Supple-
mental Data for details.CSupplemental Data
The Supplemental Data include ten supplemental figures and Supple-
mental Experimental Procedures and can be found with this article
online at http://www.cancercell.org/cgi/content/full/12/4/328/DC1/.
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